Acsel Health, an OPEN Health Company
Written on Saturday 1st May 2021
This 2-day event brought together the global community to discuss worldwide trends influencing patient access to safe and effective therapies.
The world of health economics and outcomes research (HEOR) has grown considerably since the 1990s, when the first pharmacoeconomic guidelines were released in Australia and Canada and health technology assessment (HTA) agencies such as NICE in the UK were formed. Today, the quest for robust scientific evidence continues. Healthcare decision-makers require high-quality data that describe unmet therapeutic needs and endorse innovative treatment strategies meeting those needs. Regulatory approval no longer guarantees patient access, the so-called “fourth hurdle,” and demonstrating the value of innovative therapies must be supported.
Despite the challenging environment, there is good news—we at OPEN Health firmly believe that patient access is very much achievable if the right market access and integrated evidence-generation strategies are in place.
An exciting and information-rich agenda where expert OPEN Health presenters will addressed topics of critical importance to the pharmaceutical industry, including: